Using Progesterone to Prevent Preterm Birth in Multiple Pregnancies
Author Information
Author(s): Lim Arianne C, Bloemenkamp Kitty WM, Boer Kees, Duvekot Johannes J, Erwich Jan Jaap HM, Hasaart Tom HM, Hummel Pieter, Mol Ben WJ, Offermans Jos PM, van Oirschot Charlotte M, Santema Job G, Scheepers Hubertina CJ, Schöls Willem A, Vandenbussche Frank PHA, Wouters Maurice GAJ, Bruinse Hein W
Primary Institution: Academic Medical Centre, Amsterdam, the Netherlands
Hypothesis
17OHPC will reduce the incidence of the composite neonatal morbidity of neonates by reducing the early preterm birth rate in multiple pregnancies.
Conclusion
The study aims to determine if progesterone treatment can effectively prevent bad neonatal outcomes due to preterm birth in multiple pregnancies.
Supporting Evidence
- 15% of multiple pregnancies end in preterm delivery, leading to significant neonatal morbidity.
- Prophylactic administration of 17OHPC has been effective in singleton pregnancies with a history of preterm birth.
- The study aims to include 660 women to assess the effectiveness of progesterone in reducing bad neonatal outcomes.
Takeaway
This study is trying to find out if giving a hormone called progesterone can help prevent early births in women who are pregnant with twins or more.
Methodology
A placebo-controlled, double-blinded randomized study comparing weekly 250 mg 17OHPC intramuscular injections versus placebo from 16–20 weeks up to 36 weeks of gestation.
Limitations
The study excludes women with previous spontaneous preterm birth < 34 weeks, serious congenital defects, or other specific conditions.
Participant Demographics
Women with multiple pregnancies at a gestational age between 15 and 20 weeks.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website